are alleviated by the reduction of plasma lp a levels we evaluated the composition of these biochemical compounds for its ability to lowering plasma lp a and other lipoproteins in humans we administered the biochemical composition containing the compounds listed in table 1 in a prospective clinical study with 14 patients various clinical parameters were recorded before the administration of the composition blood samples were collected via venipuncture at the beginning of the study and plasma levels of various lipoproteins were monitored with elisa assays the ages of this group of 14 patients ranged from 34 to 68 years old this group of human subjects were clinically classified as polygenic hyperlipidemia the average plasma level of lp a was 71 mg dl the average plasma total cholesterol level was 293 mg dl the average plasma ldl cholesterol level was 195 mg dl the average plasma triglyceride level was 193 mg dl these patients received the biochemical compounds listed in table 1 as a daily dosage the patients received the compounds of the invention for a period of three months at the end of the three months after the therapeutic intervention blood samples were again collected via venipuncture at the end of the study plasma concentrations of various lipoproteins were monitored with elisa assays results of the study as illustrated in fig1 and fig2 demonstrates that the patents after therapeutic administration of compositions had led to the following average decrease in plasma levels of 1 lp a from 71 mg dl to 64 mg dl a decrease of 13 2 total cholesterol from 293 mg dl to 252 mg dl a.